» Articles » PMID: 11212268

Homozygous Deletion of CDKN2A (p16INK4a/p14ARF) but Not Within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Feb 24
PMID 11212268
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Loss of heterozygosity of several specific genomic regions is frequently observed in neuroblastoma tumors and cell lines, but homozygous deletion (HD) is rare, and no neuroblastoma tumor suppressor gene (TSG) has yet been identified. We performed a systematic search for HD, indicative of a disrupted TSG, in a panel of 46 neuroblastoma cell lines. An initial search focused on a well-characterized consensus region of hemizygous deletion at 1p36.3, which occurs in 35% of primary neuroblastomas. Each cell line was screened with 162 1p36 markers, for a resolution of 13 kb within the consensus 1p36.3 deletion region and 350 kb throughout the remainder of 1p36. No HDs were detected. This approach was expanded to survey 21 known TSGs, specifically targeting intragenic regions frequently inactivated in other malignancies. HD was detected only at the CDKN2A (p16INK4a/p14ARF) gene at 9p21 and was observed in 4 of 46 cell lines. The observed region of HD included all exons of both CDKN2A and the closely linked CDKN2B (p15INK4b) gene for cell lines LA-N-6 and CHLA-174, all exons of CDKN2A but none of CDKN2B for CHLA-179, and only 104 bp within CDKN2A exon 2 for CHLA-101. All four deletions are predicted to inactivate the coding regions of both p16INK4a and p14ARF. HD was observed in corresponding primary tumor samples for CHLA-101 and CHLA-174 but was not present in constitutional samples. These results suggest that for neuroblastoma, large HDs do not occur within 1p36, most known TSGs are not homozygously deleted, and biallelic inactivation of CDKN2A may contribute to tumorigenicity in a subset of cases.

Citing Articles

The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner.

Mazar J, Brooks J, Peloquin M, Rosario R, Sutton E, Longo M Cancer Res Commun. 2024; 4(1):65-80.

PMID: 38214542 PMC: 10775766. DOI: 10.1158/2767-9764.CRC-23-0221.


Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma.

Peng Y, Chen Y, Song M, Zhang X, Li P, Yu X Mol Oncol. 2022; 16(8):1746-1760.

PMID: 35253368 PMC: 9019898. DOI: 10.1002/1878-0261.13206.


The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.

Mazar J, Gordon C, Naga V, Westmoreland T Anticancer Agents Med Chem. 2020; 20(13):1613-1625.

PMID: 32329693 PMC: 7527568. DOI: 10.2174/1871520620666200424123834.


Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.

Wu H, Sheard M, Malvar J, Fernandez G, DeClerck Y, Blavier L Clin Cancer Res. 2019; 25(15):4761-4774.

PMID: 31068371 PMC: 6738573. DOI: 10.1158/1078-0432.CCR-18-3358.


Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.

Wang Y, Chen K, Cai Y, Cai Y, Yuan X, Wang L J Exp Clin Cancer Res. 2017; 36(1):111.

PMID: 28814318 PMC: 5559827. DOI: 10.1186/s13046-017-0581-6.